Mesoblast (ASX:MSB) was the top performer for the year up 835% (as of December 30). On December 18 Mesoblast announced that the US Food and Drug Administration (FDA) had finally approved its therapy ...

There are also links to our five key questions and their corresponding quality statements, which are related to each PIR question. Reading these will give you a better understanding of our ...